Daily Briefing – June 10: May CPI confirmed at +4.2% (in line with consensus), Iran-USA escalation, markets sold off yesterday, Oracle earnings tonight with $553B AI backlog

The June 10, 2026 briefing opens with three simultaneous macro forces making this one of the most catalyst-dense sessions of the year. First: May CPI confirmed consensus exactly: +4.2% year-over-year — the first reading above 4% since May 2023 and the highest in three years — with a monthly gain of +0.5% (SA) and core +2.9%, driven by energy costs (+3.9% for the month, accounting for over 60% of the total monthly increase) tied to the Iran war. Second: the U.S.-Iran military conflict escalated overnight with new American strikes following the downing of an Apache helicopter near the Strait of Hormuz, and Iran responded with missiles and drones against U.S. bases in Kuwait (international airport hit, flights suspended), Bahrain and Jordan. Third: Oracle reports fiscal Q4 results tonight after the close, with a record $553 billion AI backlog on the table and options pricing in a 13% swing in either direction. Markets priced all of this in yesterday: Nasdaq -1% to 25,678, tech sector -2%, Apple -3% after the EU blocked its new Siri AI for antitrust reasons, Nvidia -3%, AMD -1%. In Italy, the Ponte Messina corruption scandal dominates front pages with three people under investigation by the Rome prosecutor’s office.

• May CPI— Confirmed: +4.2% YoY, exactly in line with consensus (vs. +3.8% in April). Monthly: +0.5% SA. Core: +2.9%. Energy: +3.9% for the month — accounting for over 60% of the total monthly increase. First reading above 4% since May 2023. This print rules out any near-term Fed rate cuts.Macro / CPI
• ORCL— Oracle reports Q4 FY2026 tonight after the close (call at 4:00 p.m. Central Time). Record AI backlog of $553 billion. EPS consensus: $1.96. Options pricing: ±13% swing. Strong Buy from 28 of 33 analysts. Key test on cloud revenue, backlog conversion and margins.AI Earnings
• AAPL— Apple fell 3% yesterday after the EU blocked the launch of its new Siri AI on antitrust grounds. The market reads this as a signal that Apple’s AI monetization outside the U.S. will be slower and more complex than anticipated.AI / EU Antitrust
• NVDA— Nvidia lost 3% in yesterday’s broad tech sell-off. It remains the anchor of the AI trade but needs to demonstrate stabilization in an environment of high rates, geopolitical risk and rising CPI.AI Leader
• MRVL— Marvell remains one of the most active AI names ahead of its S&P 500 inclusion before the open on June 22. It combines custom silicon, AI data-center exposure and expected passive benchmark flows.AI / Index
• FLEX— Flex will enter the S&P 500 alongside Marvell on June 22, adding a benchmark-flow angle to a business tied to manufacturing, supply chain and technology infrastructure.Index Flow
• AVGO— Broadcom remains a key thermometer for AI infrastructure demand. Quality and demand stay solid, but the market now requires more discipline on valuations in a macro environment complicated by war and elevated CPI.AI Reset
• AMD / INTC— AMD -1% yesterday. Both AMD and Intel are chip-breadth checks: a real AI rebound requires secondary semiconductor names to recover, not just the most crowded leaders.Chip Breadth
• Biotech M&A— Deal flow at $106 billion YTD across 201 transactions: the sector is on track for its best year since pre-Covid. Drivers: patent cliffs, recovering IPO markets, Big Pharma pipeline hunger. Focus on bolt-on deals in the $1–5 billion range.Pharma M&A
• VRDN— Viridian is the hottest near-term biotech name: veligrotug is under Priority Review with a June 30, 2026 PDUFA target date in thyroid eye disease. One of the closest catalysts on the calendar.PDUFA Watch
• Parabilis Medicines IPO— The biotech set terms for an IPO of up to $475 million, the second-largest sector offering of the year. A signal that the biotech primary market is still open for business.Biotech IPO
• GILD / MRK— Yesterday’s positive Phase 3 topline data for islatravir/lenacapavir as a once-weekly oral HIV treatment remain relevant today. The long-acting chronic-disease treatment theme continues to gain traction with investors.HIV / Phase 3
• COGT / BBIO / VERA / CORT / CAPR— The FDA basket remains central in a selective tape: regulatory timing, cash runway and dilution risk matter as much as the catalyst itself. Read these names as a set, not in isolation.Biotech FDA
• XBI— XBI is the main sector check: the confirmed CPI print and continued M&A flow will determine whether biotech risk appetite can hold or whether the market keeps rewarding only isolated single-stock stories.Biotech Tape
• Ponte Messina (Italy)— Rome prosecutors are investigating three people for corruption linked to the Strait of Messina Bridge project: ex-senior Corte dei Conti judge Tommaso Miele, businessman Vincenzo Virgiglio and lawyer Giacomo Saccomanno. Alleged scheme: pressuring the court of auditors in exchange for future public appointments. On every Italian newspaper front page this morning.Italy / Politics

• Iran-USA: overnight escalation— New U.S. strikes overnight following the downing of an Apache helicopter near the Strait of Hormuz. Iran retaliated with missiles and drones against 21 U.S. targets in Kuwait (airport hit, flights suspended), Bahrain and Jordan. Trump says negotiations continue despite the escalation.Geopolitics
• CPI: +4.2% confirmed — no surprise in either direction— The print landed exactly at consensus. No shock in either direction: the door to near-term Fed cuts stays firmly closed, and pressure on bond yields, growth multiples and the long end of the curve remains fully intact.Inflation
• Oil: still a live variable— Crude remains the first-order geopolitical indicator. Any new spike immediately reopens the inflation, margin and rate-pressure debate. Kuwait is the new regional flashpoint to watch.Oil / Geo
• Bond yields: confirmed CPI holds the pressure— Yields remain the key constraint for growth, small caps, high-valuation AI and cash-burning biotech. The +4.2% print keeps pressure on the long end of the curve unchanged.Rates
• AI faces an increasingly tough review— After Apple’s EU Siri block and yesterday’s sell-off, the market is demanding real delivery, margins, backlog conversion and cash flow. Oracle tonight is the next hard test of whether AI infrastructure spend is translating into profit.AI Valuation
• Apple: consumer-AI test post-EU ruling— The EU antitrust block on new Siri is not just a legal story: it signals Apple’s AI roadmap outside the U.S. is more complicated than the market expected. The question is how much this weighs on the upgrade cycle thesis.AAPL
• Oracle: the cloud-AI profitability gate— With $553 billion in AI backlog, tonight’s Q4 answers one critical question: how much of that pipeline is converting into revenue, margins and cash? The market has already priced in a 13% swing.ORCL
• Tariffs: Section 122 expires in July— The 10% across-the-board import surcharge remains in effect (under appeal), but the Section 122 authority expires July 24 without a Congressional extension. New forced-labor tariffs of 10% have been proposed on 16 economies including the EU, UK and Canada.Trade
• Biotech: deal flow as selective support— $106 billion in M&A YTD proves Big Pharma is still paying for differentiated innovation. But in a difficult macro environment, quality, cash runway and credible regulatory paths are rewarded over broad sector speculation.Biotech
• World Cup 2026: starts tomorrow— The tournament opens Friday, June 11 at the Estadio Azteca with Mexico vs. South Africa. Tonight’s countdown concerts in host cities. First global consumer and advertising-spend impact begins now.Sports / Macro